Ensuring exchangeability in data‐based priors for a Bayesian analysis of clinical trials

In many orphan diseases and pediatric indications, the randomized controlled trials may be infeasible because of their size, duration, and cost. Leveraging information on the control through a prior can potentially reduce sample size. However, unless an objective prior is used to impose complete ign...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical statistics : the journal of the pharmaceutical industry Vol. 21; no. 2; pp. 327 - 344
Main Authors Lin, Junjing, Gamalo‐Siebers, Margaret, Tiwari, Ram
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Inc 01.03.2022
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In many orphan diseases and pediatric indications, the randomized controlled trials may be infeasible because of their size, duration, and cost. Leveraging information on the control through a prior can potentially reduce sample size. However, unless an objective prior is used to impose complete ignorance for the parameter being estimated, it results in biased estimates and inflated type‐I error. Hence, it is essential to assess both the confirmatory and supplementary knowledge available during the construction of the prior to avoid “cherry‐picking” advantageous information. For this purpose, propensity score methods are employed to minimize selection bias by weighting supplemental control subjects according to their similarity in terms of pretreatment characteristics to the subjects in the current trial. The latter can be operationalized through a proposed measure of overlap in propensity‐score distributions. In this paper, we consider single experimental arm in the current trial and the control arm is completely borrowed from the supplemental data. The simulation experiments show that the proposed method reduces prior and data conflict and improves the precision of the of the average treatment effect.
Bibliography:The views expressed in this paper are those of the authors and not necessarily those of the U.S. Food and Drug Administration or the author's employers.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1539-1604
1539-1612
1539-1612
DOI:10.1002/pst.2172